ReviewCurrent oncology reports2025
Oligometastatic Esophagogastric Cancer: Does It Exist and How Do We Treat It?
Review in Current oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Survival and Pathologic Response After Neoadjuvant Treatment in Esophagogastric Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- [Oligometastasis in the gastrointestinal tract].Chirurgie (Heidelberg, Germany) · 2026Article
- Exploratory analysis of prognostic factors and hematologic dynamics in unresectable ESCC treated with concurrent versus interval immune checkpoint inhibitors combined with (chemo)radiotherapy: a multicenter real-world study.Frontiers in immunology · 2026Article
- Refining distant metastasis stage in oral squamous cell carcinoma.World journal of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewThis narrative review aims to provide an overview of recently completed randomized trials and expert consensus recommendations, and their implications for clinical practice and future trial design in patients with de-novo esophagogastric oligometastatic disease (OMD). RECENT
findingsThe IKF-575/RENAISSANCE phase III trial showed no significant overall survival difference between systemic therapy alone and systemic therapy combined with local therapy for patients with gastric or gastroesophageal junction cancer and de-novo OMD, except for patients with retroperitoneal lymph node metastases only. The ESO-Shanghai 13 phase II trial demonstrated superiority of adding local therapy to systemic therapy for progression-free and overall survival in oligometastatic esophageal squamous cell carcinoma. The OMEC project developed a multidisciplinary European consensus for OMD, proposing a restrictive definition of OMD. Clinical trial assessing the optimal treatment of care are urgently needed. The findings highlight the importance of strict patient selection for local metastasis-directed treatment and the need for stratifying patients based on histology and location of metastases. Future research should focus on identifying biomarkers and clinical features to guide multidisciplinary treatment approaches for OMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.